Adamis Pharmaceuticals Corporation (ADMP) Research

Adamis Pharmaceuticals Corporation is a specialized biopharmaceutical company primarily engaged in the development and commercialization of products within the United States, targeting key therapeutic domains such as allergy, opioid overdose, respiratory conditions, and inflammatory diseases. Its current product portfolio includes SYMJEPI pre-filled epinephrine syringes for the emergency treatment of severe allergic reactions, including anaphylaxis; dry powder inhaler products designed for asthma management; and injectable naloxone for addressing opioid overdose. Additionally, Adamis is advancing pipeline candidates such as APC400, a tempol gel aimed at mitigating radiation-induced dermatitis in cancer patients, and APC410, formulated to treat a range of respiratory ailments including asthma, respiratory syncytial virus (RSV), influenza, and COVID-19. The company also extends its offerings to include corticosteroids, hormone replacement therapies, hospital outsourcing products, and other injectables, alongside a line of veterinary pharmaceutical products. Established in 2006, Adamis Pharmaceuticals Corporation maintains its headquarters in San Diego, California.

Open Adamis Pharmaceuticals Corporation (ADMP) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.